Canada Spends Logo

Explore our Budget 2026 analysis

Grant: Master's Award: Canada Graduate Scholarships

University of British Columbia

$17,500.00

A synthetic model of human T-cell acute lymphoblastic leukemia in primary cord blood cells.

FY 2016-17

Summary
The leukemogenesis of normal hematopoietic progenitors into the malignant, immature T-cell blasts of T-cell acute lymphoblastic leukemia (T-ALL) is dependent on the cooperative effect of many genetic lesions. Notch1, LMO2, and TAL1 are all oncogenes frequently over-expressed in human T-ALL patients while CDKN2A is a locus that codes for the tumor suppressor genes iNK4A/p14 and ARF/p19 and is frequently repressed in T-ALL cases. Repression of CDKN2A can also be induced by overexpressing BMI1. We recently created a synthetic T-ALL by introducing the oncogenes Notch1, LMO2, TAL1, and BMI1 into normal human cord blood progenitor cells (CD34+) using lentiviral delivery. My hypothesis is that this model of human T-ALL requires all four oncogenes and that BMI1 is important primarily due to its repression of INK4A/ARF expression. To test this, we will perform leave one out experiments where human cord blood progenitors are transduced with each combination of only three oncogenes to determine the importance of each gene. Also, cells will be transduced with Notch1, LMO2, TAL1 and a shRNA against CDKN2A to clarify the oncogenic function of BMI1 with respect to INK4A/ARF repression. Growth and differentiation of in vitro cultures will be monitored using multi-colour flow cytometry while leukemogenesis will be assayed in vivo with transplantation into immunodeficient (NSG) mice. Disease latency will be measured and leukemic transformation of these cells will then be validated through serial transplantation into secondary recipients. These studies will further characterize the components of this novel, synthetic human T-ALL model and increase understanding of T-ALL leukemogenesis.
Program
Master's Award: Canada Graduate Scholarships
Location
British Columbia, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database

As published

Id
367344
Name
Sun Chong
Region
British Columbia
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
A synthetic model of human T-cell acute lymphoblastic leukemia in primary cord blood cells.
Programtype2
Studentship Programs
Orgnameinp2
University of British Columbia
Cihramount2
$17,500
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Scholarships
Keyworddelim
Cancer Stem Cells; Human Model; Lentivirual Transductions; Leukemia; Leukemia Initiating Cells; Leukemogenesis; Nsg Mice; Oncogenes; T-Cells
Abstract
The leukemogenesis of normal hematopoietic progenitors into the malignant, immature T-cell blasts of T-cell acute lymphoblastic leukemia (T-ALL) is dependent on the cooperative effect of many genetic lesions. Notch1, LMO2, and TAL1 are all oncogenes frequently over-expressed in human T-ALL patients while CDKN2A is a locus that codes for the tumor suppressor genes iNK4A/p14 and ARF/p19 and is frequently repressed in T-ALL cases. Repression of CDKN2A can also be induced by overexpressing BMI1. We recently created a synthetic T-ALL by introducing the oncogenes Notch1, LMO2, TAL1, and BMI1 into normal human cord blood progenitor cells (CD34+) using lentiviral delivery. My hypothesis is that this model of human T-ALL requires all four oncogenes and that BMI1 is important primarily due to its repression of INK4A/ARF expression. To test this, we will perform leave one out experiments where human cord blood progenitors are transduced with each combination of only three oncogenes to determine the importance of each gene. Also, cells will be transduced with Notch1, LMO2, TAL1 and a shRNA against CDKN2A to clarify the oncogenic function of BMI1 with respect to INK4A/ARF repression. Growth and differentiation of in vitro cultures will be monitored using multi-colour flow cytometry while leukemogenesis will be assayed in vivo with transplantation into immunodeficient (NSG) mice. Disease latency will be measured and leukemic transformation of these cells will then be validated through serial transplantation into secondary recipients. These studies will further characterize the components of this novel, synthetic human T-ALL model and increase understanding of T-ALL leukemogenesis.
Competitiondate
201612
Approvedterm2
1 yr 0 mth
Pinamesdelim
Sun, Chong
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $17,500~ $0~